| Date | Title | | | 12/13/11 | MannKind Resolves All Claims in Arbitration with Former Employee| VALENCIA, Calif.--(BUSINESS WIRE)--Dec. 13, 2011--
MannKind Corporation (Nasdaq: MNKD) announced today that it
reached a final resolution of the arbitration proceedings initiated by
John Arditi, MannKind’s former Senior Director - GCP - Regulatory
Affairs. During his employment with MannKind, Mr. Arditi played a key
role in preparing clinical sites for FDA inspection and was responsible
for the company’s GCP compliance audit program.
I... |
|  | | 11/08/11 | MannKind to Present at Upcoming Conferences| VALENCIA, Calif., Nov 08, 2011 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences.
The Lazard Capital Markets 8th Annual Healthcare Conference on November 15, 2011 at 1:30pm ET at The Pierre Hotel in New York, New York
The 23rd Annual Piper Jaffray Health Care Conference on November 30, 2011 at 9:00am ET at The New York Palace in New ... |
| | | 11/03/11 | MannKind Corporation Reports 2011 Third Quarter Financial Results| - Conference Call to Begin Today at 5:00 PM ET -
VALENCIA, Calif., Nov 03, 2011 (BUSINESS WIRE) -- MannKind Corporation (NASDAQ: MNKD) today reported financial results for the third quarter ended September 30, 2011.
For the third quarter of 2011 total operating expenses were $32.8 million, compared to $42.5 million for the third quarter of 2010, a decrease of $9.7 million. The decrease primarily relates to an $8.3 million decrease in research and development (R&D) expenses. This 26% decre... |
| | | 10/28/11 | MannKind Corporation to Hold 2011 Third Quarter Financial Results Conference Call on November 3, 2011| VALENCIA, Calif., Oct 28, 2011 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2011 third quarter financial results on Thursday, November 3, 2011 and its management will host a conference call to discuss the third quarter financial results and other Company developments at 5:00 PM (Eastern Time) on November 3, 2011.
Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann, President and Chief Operating Officer, Hakan Edstrom, Corporate V... |
| | | 10/14/11 | MannKind to Present at The 18th Annual Newsmakers in the BioTech Industry Conference | VALENCIA, Calif., Oct 14, 2011 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the 18th Annual Newsmakers in the BioTech Industry Conference presented by Thomson Reuters and BioCentury on Friday, October 21, 2011 at 8:30am (ET) at the Millennium Broadway Hotel in New York, New York.
Interested parties can access a link to the live webcast of the presentatio... |
| | | 09/23/11 | MannKind Announces Proposed Offering of Senior Secured Discount Notes
Due 2017| VALENCIA, Calif., Sep 23, 2011 (BUSINESS WIRE) --MannKind Corporation (Nasdaq: MNKD) today announced that it
proposes to offer, subject to market conditions, senior secured discount
notes due 2017 (the "Notes") expected to yield gross proceeds of
approximately $370.0 million.
If the offering is consummated, the net proceeds from the offering of
the notes would be used for development and operating capital, including
completion of the Phase 3 clinical ... |
| | | 09/22/11 | MannKind to Present at Upcoming Conferences| VALENCIA, Calif., Sep 22, 2011 (BUSINESS WIRE) --MannKind Corporation (Nasdaq: MNKD), focused on discovering,
developing and commercializing treatments for diabetes and cancer,
announced today that it will present at upcoming conferences.
The Sixth Annual JMP Securities Healthcare Conference on September 28,
2011 at 12:30 p.m. ET at the St. Regis in New York, New York
The Fifth Annual Global Opportunities Conference presen... |
| | | 09/06/11 | MannKind to Present at Rodman & Renshaw Annual Global Investment Conference| VALENCIA, Calif., Sep 06, 2011 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 12, 2011 at 10:00 AM (ET) at the Waldorf-Astoria in New York, New York.
Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company... |
| | | 08/11/11 | MannKind Confirms Design of Pivotal Studies| VALENCIA, Calif., Aug 11, 2011 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that it has confirmed with the U.S. Food and Drug Administration the design of two clinical studies that evaluate the efficacy and safety of AFREZZA(R) (insulin human [rDNA origin]), an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind's next-generation inhaler. The FDA had previously requested that MannKind conduct two clinical trials with the next-genera... |
| | | 08/04/11 | MannKind Corporation Reports 2011 Second Quarter Financial Results| - Conference Call to Begin Today at 5:00 PM ET -
VALENCIA, Calif., Aug 04, 2011 (BUSINESS WIRE) -- MannKind Corporation (NASDAQ: MNKD) today reported financial results for the second quarter ended June 30, 2011.
For the second quarter of 2011 total operating expenses were $39.2 million, compared to $37.4 million for the second quarter of 2010, an increase of $1.8 million. Research and development (R&D) expenses were $30.3 million for the second quarter of 2011 compared to $26.2 million ... |
| | | 07/28/11 | MannKind Corporation to Hold 2011 Second Quarter Financial ResultsConference Call on August 4, 2011| VALENCIA, Calif., Jul 28, 2011 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2011 second quarter financial results on Thursday, August 4, 2011 and its management will host a conference call to discuss the second quarter financial results and other Company developments at 5:00 PM (Eastern Time) on August 4, 2011.
Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; Corporate Vice... |
| | | 06/24/11 | Studies Show No Increased Risk of Cardiac Events in Diabetes Patients Treated with AFREZZA(R)| Latest safety data to be highlighted at the American Diabetes Association's 71st Scientific Sessions
SAN DIEGO, Jun 24, 2011 (BUSINESS WIRE) -- The findings of two separate studies further substantiate that treatment with the investigational ultra rapid acting mealtime insulin AFREZZA(R) (insulin human [rDNA origin]) Inhalation Powder does not result in excess cardiovascular events in type 1 or type 2 diabetes patients. Furthermore, results demonstrate that inhaled AFREZZA did not produce cli... |
| | | 06/24/11 | Type 1 Diabetes Patients Using AFREZZA Have More Positive View of Therapy Compared to Standard Insulin Therapy| Significantly improved perceptions of convenience, comfort, and ease of regimen adherence of insulin therapy reported by patients using ultra rapid acting mealtime inhaled insulin
Data to be presented at the American Diabetes Association's 71st Scientific Sessions
SAN DIEGO, Jun 24, 2011 (BUSINESS WIRE) -- Results of a new patient-reported outcomes (PRO) study show that patients with type 1 diabetes who received the investigational ultra rapid acting mealtime insulin, AFREZZA(R) (insulin h... |
| | | 06/16/11 | MannKind to Present at the Wells Fargo Securities 2011 Healthcare Conference| VALENCIA, Calif., Jun 16, 2011 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Wells Fargo Securities 2011 Healthcare Conference on Thursday, June 23, 2011 at 11:15 AM (ET) at The InterContinental Hotel in Boston, Massachusetts.
Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company... |
| | | 05/31/11 | MannKind to Present at the Jefferies 2011 Global Healthcare Conference| VALENCIA, Calif., May 31, 2011 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011 at 4:00 PM (ET) in New York.
Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company's website at www.mannkindcorp.com.
About MannKind... |
| | | 05/09/11 | MannKind Corporation Reports 2011 First Quarter Financial Results| - Conference Call to Begin Today at 4:30 PM EDT -
VALENCIA, Calif., May 09, 2011 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the first quarter ended March 31, 2011.
For the first quarter of 2011 total operating expenses were $38.1 million, compared to $40.6 million for the first quarter of 2010. Research and development (R&D) expenses were $26.3 million for the first quarter of 2011 compared to $30.5 million for the same quarter in 2010, a ... |
| | | 04/26/11 | MannKind to Present at Upcoming Conferences| VALENCIA, Calif., Apr 26, 2011 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences.
Deutsche Bank Securities 36th Annual Health Care Conference on May 3, 2011 at 4:10 ET at the InterContinental Boston in Boston, Massachusetts
Bank of America Merrill Lynch 2011 Health Care Conference on May 11, 2011 at 5:20 ET at the Encore Hotel in La... |
| | | 04/19/11 | MannKind Corporation to Hold 2011 First Quarter Financial Results Conference Call on May 9, 2011| VALENCIA, Calif., Apr 19, 2011 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2011 first quarter financial results on Monday, May 9, 2011 and its management will host a conference call to discuss the first quarter financial results and other Company developments at 4:30 PM (Eastern Time) on May 9, 2011. The first quarter conference call was rescheduled from April 25, 2011 in order to provide an opportunity for management to comment on an End-of-Review meeting scheduled t... |
| | | 04/12/11 | MannKind's End-of-Review Meeting with FDA Rescheduled| VALENCIA, Calif., Apr 12, 2011 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq:MNKD) announced today that its End-of-Review (EOR) meeting with the U.S. Food & Drug Administration (FDA) is now scheduled to be held on May 4th. Last Friday, in order to prepare for a potential shutdown of non-critical government operations, the FDA cancelled its internal meeting to prepare for the EOR meeting regarding AFREZZA, necessitating a cancellation of the EOR meeting itself, which had been scheduled for ... |
| | | 04/08/11 | MannKind Provides Regulatory Update| VALENCIA, Calif., Apr 08, 2011 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that it was informed by the U.S. Food & Drug Administration (FDA) that due to a potential government shutdown the FDA has decided to cancel an End-of-Review meeting with MannKind that was to be held on April 15, 2011. The FDA stated that when it is able to do so it will reschedule the meeting to the next possible date. MannKind will provide a further update about its planned interactions wit... |
| | | 04/05/11 | MannKind Posters Win Awards from International Pharmaceutical Aerosol Consortium on Regulation and Science| DANBURY, Conn., Apr 05, 2011 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that it was awarded two poster awards at the 2011 conference of the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS), held March 29-31 in Rockville, Maryland. IPAC-RS is an international association of companies that develop, manufacture or market orally inhaled and nasal drug products for local and systemic treatment of a variety of debilitating diseases such as... |
| | | 02/22/11 | MannKind to Present at the Citi 2011 Global Healthcare Conference| VALENCIA, Calif., Feb 22, 2011 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Citi 2011 Global Healthcare Conference on Tuesday, March 1, 2011 at 2:30 PM (ET) at the Hilton New York in New York, New York.
Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company's website at www.mannk... |
| | | 02/10/11 | MannKind Corporation Reports 2010 Fourth Quarter and Full Year Financial Results| - Conference Call to Begin Today at 4:30 PM EST -
VALENCIA, Calif., Feb 10, 2011 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the fourth quarter and year ended December 31, 2010.
For the fourth quarter of 2010, total operating expenses were $32.1 million, compared to $55.8 million for the fourth quarter of 2009, a decrease of $23.7 million. Research and development (R&D) expenses were $24.2 million for the fourth quarter of 2010 compared to ... |
| | | 02/08/11 | MannKind to Present at the 13th Annual BIO CEO & Investor Conference| VALENCIA, Calif., Feb 08, 2011 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the 13th Annual BIO CEO & Investor Conference on Tuesday, February 15, 2011 at 11:00 AM (ET) at the Waldorf Astoria in New York, New York.
Interested parties can access a link to the live webcast of the presentation from the News & Media section of the Company's website at www.ma... |
| | | 01/27/11 | MannKind Corporation to Hold 2010 Fourth Quarter and Full Year Financial Results Conference Call on February 10, 2011| VALENCIA, Calif., Jan 27, 2011 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2010 fourth quarter and full year financial results on Thursday, February 10, 2011.
Management of the Company will host a conference call to discuss the fourth quarter and full year financial results and other Company developments at 4:30 PM (Eastern Time) on February 10, 2011. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operat... |
| | | 01/19/11 | MannKind Corporation Receives Complete Response Letter from the FDA
for AFREZZA(R)| VALENCIA, Calif., Jan 19, 2011 (BUSINESS WIRE) --MannKind Corporation (Nasdaq: MNKD) today announced that it has received
a complete response letter from the U.S. Food & Drug Administration
(FDA) regarding the New Drug Application (NDA) for AFREZZA(R)
(insulin human [rDNA origin]) Inhalation Powder for the treatment of
adult patients with type 1 and type 2 diabetes for the control of
hyperglycemia.
A complete response letter is issued by the FDA's... |
| | | 01/04/11 | MannKind to Present at the JP Morgan 29th Annual Healthcare Conference | VALENCIA, Calif., Jan 04, 2011 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the JP Morgan Healthcare Conference on Wednesday, January 12, 2011 at 3:00 PM (PT) at the Westin St. Francis Hotel in San Francisco, California.
Interested parties can access a link to the live webcast of the presentation from the News & Media section of the Company's website at ... |
| |
|
